Latest Content

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.

Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.

Nearly 72% of patients hospitalized for heart failure had 2 or more other CKM conditions, with the strongest links to poor outcomes in HFrEF.

Posters in an artificial intelligence and digital care session at Kidney Week 2026 spanned CKD risk prediction and LLM-drafted prior authorization letters.

Among nearly 48 million US adults eligible for obesity medications, oral semaglutide initiation climbed quickly after its December 2025 FDA approval.

As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.

Clinicians from University of Chicago Medicine, Northwestern Medicine, and Loyola Medicine said bispecific antibodies for early-relapse myeloma can be given safely outside the hospital, but staffing, after-hours triage, and community confidence have yet to catch up.

A 35-year Danish registry study found MACE declined in every income quartile, but the lowest earners kept higher rates than top earners throughout.

Low-dose CT (LDCT) screening for individuals with a family history of lung cancer was cost-effective using Taiwan-based parameters; future work should incorporate real-world program data and subgroup analyses.